about
Effectiveness of anti-psychotics and related drugs in the Huntington French-speaking group cohort[Systemic lupus erythematosus presenting with recurrent psychiatric disturbances]Association between caffeine intake and age at onset in Huntington's disease.External globus pallidus stimulation modulates brain connectivity in Huntington's disease.Longitudinal study of informed consent in innovative therapy research: experience and provisional recommendations from a multicenter trial of intracerebral grafting.COMT Val158Met Polymorphism Modulates Huntington's Disease Progression.Embryonic stem cells: meeting the needs for cell therapy.Idiopathic hypertrophic cranial pachymeningitis treated by oral methotrexate: a case report and review of literature.A randomized, double-blind, placebo-controlled trial evaluating cysteamine in Huntington's disease.RNA-binding disturbances as a continuum from spinocerebellar ataxia type 2 to Parkinson disease.A genetic variation in the ADORA2A gene modifies age at onset in Huntington's disease.High insulinlike growth factor I is associated with cognitive decline in Huntington disease.Are gait initiation parameters early markers of Huntington's disease in pre-manifest mutation carriers?Engraftable human neural stem cells respond to developmental cues, replace neurons, and express foreign genes.Le traitement par apomorphine en perfusion continue sous-cutanée dans la maladie de Parkinson : analyse rétrospective d’une série de 81 patientsAttenuated presentation of ataxia-telangiectasia with familial cancer history[Primary treatment of Parkinson's disease: the application of the March 2000 consensus rules in the Nord Pas-de-Calais area]Neurological picture. Acquired hepatocerebral degeneration revealed by neurogenic hyperventilation syndrome and myelitis
P50
Q28538703-2EAE58FC-9DA9-463E-AC14-FB78C70A70D8Q30966801-30091442-4FE4-4B00-9EAA-721CEC09DF31Q34348412-C0490CDB-FDC0-4AB9-A524-12694EEC6821Q34627479-5FE0AF68-C0F7-49C4-BCF1-8ACCC21E915CQ35641238-D2691DC3-D843-4A8D-A59D-CF6A17C99665Q36140827-D9C0BA3A-E39D-4274-89BE-DB80EC69636AQ36300478-3738EBF6-E585-4DBB-BDB9-F358934462B4Q37038511-27D53876-951F-40D4-9203-26918E584A94Q38691678-3FFF98F0-49F7-46C1-8DEE-5DD10A5D3393Q39356825-54E75E77-5278-4729-A84B-BADB2E65EAB3Q45294471-0EEEABC4-9BAC-43B8-899F-51F0247C369FQ45298701-1892F030-9DA7-4753-8AC1-18831BC4ACFCQ45303026-7CB5A77E-0766-4603-9533-48F88BD00DC4Q45890216-294EC206-CB40-46D9-A7C0-8854090B393DQ57666983-5928E173-3491-4477-88A8-8299A1B8310CQ57667091-D2FC6B59-3843-4FE2-8731-90011D1D0C21Q81153331-A6CFC45F-9191-4933-8913-075465030286Q84545560-CBADCD64-31BC-452F-9475-D862FADA2C47
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Clémence Simonin
@ast
Clémence Simonin
@en
Clémence Simonin
@es
Clémence Simonin
@nl
type
label
Clémence Simonin
@ast
Clémence Simonin
@en
Clémence Simonin
@es
Clémence Simonin
@nl
prefLabel
Clémence Simonin
@ast
Clémence Simonin
@en
Clémence Simonin
@es
Clémence Simonin
@nl
P106
P31
P496
0000-0002-2282-4372